Skip to main content
Blood Advances logoLink to Blood Advances
. 2022 Dec 6;6(23):6039. doi: 10.1182/bloodadvances.2022008993

Narkhede M, Goyal G, Shea L, et al. Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma. Blood Adv. 2022; 6(14):4122-4131.

PMCID: PMC9731874  PMID: 36454607

After publication, an error in the analysis of the data was discovered. The authors realized that the description of the presence of a TP53 mutation on next-generation sequencing (NGS) in the article is incorrect and that the data set they analyzed had details of deletion 17p from fluorescent in situ hybridization (FISH) and cytogenetics/karyotype studies only. Therefore, any mention of TP53 mutation or TP53 deletion in the article reflects deletion 17p from FISH and/or cytogenetics instead. The conclusion and major findings of this article are not impacted by this error.

In the visual abstract, the Venn diagram in the lower left with the heading “Positive TP53 mutation by NGS and deletion 17p by FISH when both testing available” should be disregarded.

On page 4125, in Table 1, the section “Both NGS and FISH testing available” should be disregarded.

On page 4128, Figure 4 should also be disregarded, as should the figure’s in-text citation on pages 4125 and 4126: “There was no difference in outcomes with del17p/TP53 mutated MCL between those with del17p on FISH analysis compared with the presence of TP53 mutation by NGS only (Figure 4).”


Articles from Blood Advances are provided here courtesy of The American Society of Hematology

RESOURCES